|
| | | | | | | | | | | | |
| Name | Indication | Phase | Economics | Administration | Mechanism | Competition | IP | | Price | 16 | |
| TPOXX (tecovirimat) | Smallpox | II | 100% (ongoing litigation) | Capsule | orthopoxvirus egress inhibitor | BAVA, CMRX, EBS | 2023 | | Shares | 72.566367 | Q122 |
| Dengue Virus program | Dengue Fever | Pre-clinical | 1 | TBD | anti-viral | SNY | 2026 | | MC | 1161.061872 | |
| ST-193 | Lassa Fever | Pre-clinical | 1 | TBD | anti-viral | ribavirin | 2026 | | Cash | 153.259914 | Q122 |
| ST-294 | Arenaviruses | Pre-clinical | 1 | TBD | anti-viral | ribavirin | 2026 | | Debt | 0 | Q122 |
| ST-383 | Ebola, Marburg | Pre-clinical | 1 | TBD | anti-viral | siRNA | 2026 | | EV | 1007.801958 | |
| ST-669 | Viral Infection | Pre-clinical | 1 | TBD | anti-viral | siRNA | 2026 | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | August 10, 2014: Judge rules PharmAthene is entitled to a lump sum damage award in a still unspecified amount, Siga to appeal | | | | | | | |
| | | | | August 1, 2013: Selects Lead Candidate for Dengue Antiviral Program | | | | | | | |
| | | | | July 16, 2013: Meets Drug Delivery Condition Under BARDA Contract and Qualifies for First Payment for Delivering Arestvyr | | | | | | | |
| | | | | May 26, 2013: Court Reverses Equitable Payment Stream to PharmAthene and Remands Litigation to Trial Court for New Determination of Damages | | | | | | | |
| | | | | March 12, 2013: Delivers First Courses of Arestvyr Under BARDA Contract | | | | | | | |
| | | | | June 12, 2012: Files Notice of Appeal in PharmAthene Litigation | | | | | | | |
| | | | | December 2011: Delaware court rejects SIGA appeal | | | | | | | |
| | | | | September 2011: Delaware court awards PIP 50% of SIGA's net profits on ST-246, SIGA to appeal | | | | | | | |
| | | | | June 2011: Objections to BARDA contract withdrawn, HS will purchase 1.7 million doses of STA-246 | | | | | | | |
| | | | | October 2010: SIGA awarded contract to deliver 1.7 million courses of ST-246 to HHS (RFP-BARDA-09-35) - base contract expected to generate $433 million | | | | | | | |
| | | | | February 13, 2007: Began multi-dose Phase I of ST-246 | | | | | | | |